This Blood Pressure Monitor is a digital monitor intended for use in measuring blood pressure and pulse rate with arm circumference ranging from 22cm to 32cm (about 8¾˜-12½´´), 22cm to 42cm (about 8% -16½"), 22cm to 45cm (about 8¾ -17¾ ") or 40cm to 52cm (about 15¾ -20½ "). It is intended for adult indoor use only.

Device Description

Blood Pressure Monitor TMB-2287-B is designed to measure systolic pressure, diastolic pressure and pulse rate of adult by a non-invasive technique, with an inflatable cuff wrapped around the upper arm. The method to define systolic and diastolic pressure is similar to auscultatory method, though it uses an electronic pressure sensor rather than a stethoscope and mercury manometer. The sensor converts tiny alternations of cuff pressure into electrical signals.

Based on analysis of these signals, the systolic and diastolic blood pressure is defined, and the pulse rate is calculated. This is an extensively used technique applied in blood pressure monitors, also known as "oscillometric method".

The main components of the Blood Pressure Monitor include main unit and cuff. For the outer housing of the main unit, it's made of HIPS material. As for accompanying cuffs, five types of cuffs have been clinically validated to be matched with the device, suitable for population aged at or over three and with arm circumference from 22cm~52cm. The cuff is consisted of fabric and an inflatable bladder inside. For critical electronic components, there is medical switch power supply, PCB, thermistor, pressure pump, motor, release valve and pressure sensor.

The device also enjoys a function of detecting irregular pulse rate. When measurements were performed, the monitor will record all pulse intervals and calculate the average. If two or more pulse intervals were recorded, and the difference between each interval and the average is larger than ±25% of the average; or if four or more pulse intervals were recorded, and the difference between each interval and the average is larger than ± 15% of the average, the irregular pulse symbol will be displayed along with measurement results.

An embedded Bluetooth wireless connection module in the device allows it to connect with matching receiving ends. When a measurement is done, the results will be displayed on LCD, and the measured data will be transferred to the APP via Bluetooth.

With the use of software (including APP) and Bluetooth communication module, the wireless software function and hardware function are solely intended to transfer, store, convert formats, or display medical device data and results (blood pressure and pulse rate readings), without controlling or altering the functions or parameters of any connected medical devices, which is not be intended for active patient monitoring, therefore, based on the FDA guidance titled "Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices" (issued on September 28, 2022.), this software function is belong to Non-device-MDDS, and the hardware function is belong to Device-MDDS, they are not subject to FDA laws and regulations applicable to devices.

AI/ML Overview

The provided text details the performance data for the Guangdong Transtek Medical Electronics Co., Ltd. Blood Pressure Monitor (TMB-2287-B), demonstrating its substantial equivalence to a predicate device. Here's a breakdown of the requested information:

1. Table of Acceptance Criteria and Reported Device Performance

Acceptance Criteria (Standard / Criterion)	Reported Device Performance (TMB-2287-B)
Blood Pressure Measurement Accuracy (ISO 81060-2:2018/Amd.1:2020, Criterion 1)	Study 1 (87 subjects): Mean differences between reference and device readings:- Systolic BP: -0.77 ± 2.09 mmHg- Diastolic BP: -0.08 ± 1.69 mmHgStudy 2 (91 subjects): Mean differences between reference and device readings:- Systolic BP: 0.2 ± 2.96 mmHg- Diastolic BP: 0.76 ± 3.42 mmHg
Blood Pressure Measurement Accuracy (ISO 81060-2:2018/Amd.1:2020, Criterion 2)	Study 1 (87 subjects): Mean differences between reference and device readings:- Systolic BP: -0.77 ± 1.58 mmHg- Diastolic BP: -0.08 ± 1.17 mmHgStudy 2 (91 subjects): Mean differences between reference and device readings:- Systolic BP: 0.2 ± 2.46 mmHg- Diastolic BP: 0.76 ± 2.83 mmHg
Biocompatibility (ISO 10993-1/5/10/23)	All patient contact parts meet the requirements. Testing included: Cytotoxicity, Sensitization, Irritation.
Electrical Safety (IEC 60601-1, IEC 60601-1-11)	Compliance with IEC 60601-1 (General requirements for basic safety and essential performance) and IEC 60601-1-11 (Requirements for medical electrical equipment and systems used in the home healthcare environment).
Electromagnetic Compatibility (EMC) (IEC 60601-1-2)	Compliance with IEC 60601-1-2.
Automated Non-Invasive Sphygmomanometers (IEC 80601-2-30)	Compliance with this standard.
Wireless (47 CFR Part 15, Subpart C & FDA Guidance "Radio Frequency Wireless Technology")	Compliance with 47 CFR Part 15, Subpart C, and the FDA Guidance for Radio Frequency Wireless Technology in Medical Devices. (Note: The wireless software and hardware functions are classified as Non-device-MDDS and Device-MDDS, respectively, due to their limited role in data transfer/storage without controlling device functions, and are not subject to FDA device regulations).
Blood Pressure Measurement Range	0 mmHg ~ 299 mmHg, within ±3 mmHg (0.4 kPa) for 5°C - 40°C.
Pulse Rate Measurement Range	40-199 beats/minute, ±5%.

2. Sample Size Used for the Test Set and Data Provenance

Sample Size:
- Study 1: 87 qualified subjects (258 datasets collected).
- Study 2: 91 qualified subjects (272 datasets collected).
Data Provenance: The document does not explicitly state the country of origin or whether the studies were retrospective or prospective. However, clinical validation reports typically involve prospective data collection for accuracy studies. The submitter is based in Zhongshan, Guangdong, China.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of those Experts

The document states that the clinical data was collected according to ISO 81060-2:2018/Amd.1:2020 which involves "reference BPs." While this standard requires comparisons to a reference measurement (typically auscultatory measurements by trained observers), the exact number and specific qualifications of the experts (e.g., medical professionals making the reference measurements) are not explicitly stated in the provided text.

4. Adjudication Method for the Test Set

The document does not explicitly describe an adjudication method for establishing the ground truth beyond stating that "reference BPs" were used in accordance with ISO 81060-2. This standard typically involves multiple observers taking reference measurements, and criteria are usually in place for discrepancies, but the specific method (e.g., 2+1, 3+1) is not detailed here.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was Done

No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not performed. The studies described are clinical validation studies comparing the device's readings against a reference method, not studies comparing human reader performance with and without AI assistance.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was Done

Yes, the device itself is an automated non-invasive sphygmomanometer. The clinical validation, comparing the device's measurements to reference blood pressure readings, represents a standalone performance evaluation of the algorithm and hardware without human interpretation or intervention in the measurement process itself, beyond initial setup.

7. The Type of Ground Truth Used

The ground truth for the blood pressure measurement accuracy studies was established using reference blood pressure measurements, as required by the ISO 81060-2 standard. This typically involves auscultatory measurements performed by trained medical professionals.

8. The Sample Size for the Training Set

The document does not provide information regarding a training set or its sample size. This is a medical device clearance, not a submission for an AI/ML algorithm that typically requires separate training data. The device's underlying oscillometric algorithm would have been developed and refined, but the specific "training set" for that development is not part of this regulatory submission details.

9. How the Ground Truth for the Training Set was Established

As no "training set" is disclosed in the context of this regulatory document, there is no information on how its ground truth might have been established.

Summary

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which consists of the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG" in blue, with the word "ADMINISTRATION" underneath. The logo is simple and professional, and it is easily recognizable.

April 29, 2024

Guangdong Transtek Medical Electronics Co., Ltd. Jerry Fan RA Manager Zone A, No. 105, Dongli Road, Torch Development District Zhongshan, Guangdong, China 528437

Re: K240102

Trade/Device Name: Blood Pressure Monitor (TMB-2287-B) Regulation Number: 21 CFR 870.1130 Regulation Name: Noninvasive Blood Pressure Measurement System Regulatory Class: Class II Product Code: DXN Dated: April 3, 2024 Received: April 3, 2024

Dear Jerry Fan:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"

{1}------------------------------------------------

(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review. the OS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

{2}------------------------------------------------

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Stephen C. Browning -S

LCDR Stephen Browning Assistant Director Division of Cardiac Electrophysiology, Diagnostics and Monitoring Devices Office of Cardiovascular Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

Indications for Use

Submission Number (if known)

K240102

Device Name

Blood Pressure Monitor (TMB-2287-B)

Indications for Use (Describe)

This Blood Pressure Monitor is a digital monitor intended for use in measuring blood pressure and pulse rate with arm circumference ranging from 22cm to 32cm (about 8% - 12½"), 22cm to 42cm (about 8%"-16%"), 22cm to 45cm (about 8%"-17%") or 40cm to 52cm (about 15%"-20%"). It is intended for adult indoor use only.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

X Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{4}------------------------------------------------

510(k) Summary

Prepared in accordance with the requirement of 21 CFR Part 807.92

Prepared Date: 03/11/2024

1. Submitter

Name:	Guangdong Transtek Medical Electronics Co., Ltd.
Address:	Zone A, No. 105, Dongli Road, Torch Development District, 528437 Zhongshan,Guangdong, China
Contact:	Jerry Fan
Title:	RA Manager
E-mail:	gt-rateam@transtekcorp.com
TEL:	+86 15728668528

Subject Device 2.

Trade/Device Name	Blood Pressure Monitor
Model	(TMB-2287-B)
Common Name	Blood Pressure Monitor
Classification	Class II
Product Code	DXN
Submission Type	Traditional 510(k)

Predicate Device 3.

Manufacturer:	Guangdong Transtek Medical Electronics Co., Ltd.
Device Name/Model:	Blood Pressure Monitor / TMB-2266
510(k) Number:	K232713
Classification	Class II
Product Code	DXN

4. Device Description

The device also enjoys a function of detecting irregular pulse rate. When measurements were

{5}------------------------------------------------

performed, the monitor will record all pulse intervals and calculate the average. If two or more pulse intervals were recorded, and the difference between each interval and the average is larger than ±25% of the average; or if four or more pulse intervals were recorded, and the difference between each interval and the average is larger than ± 15% of the average, the irregular pulse symbol will be displayed along with measurement results.

5. Indications for use

Item	Subject Device	Predicate Device	Note
510(k)	Applying	K232713	/
Model	TMB-2287-B	TMB-2266	/
Applicant	Guangdong Transtek MedicalElectronics Co., Ltd.	Guangdong Transtek MedicalElectronics Co., Ltd.	Same
Device Name	Blood Pressure Monitor	Blood Pressure Monitor	Same
Product Code	DXN	DXN	Same
Classification	Class II	Class II	Same
Regulation #	21 CFR 870.1130	21 CFR 870.1130	Same
Type of Use	OTC	OTC	Same
Intended Use /Indication forUse	This Blood Pressure Monitor is adigital monitor intended for use inmeasuring blood pressure and pulserate with arm circumference rangingfrom 22cm to 32cm (about8¾″-12½″), 22cm to 42cm (about	This Blood Pressure Monitor is adigital monitor intended for use inmeasuring blood pressure and pulserate with arm circumference rangingfrom 16cm to 36cm (about6⅓″-14⅕″), 22cm to 32cm (about	Similar, referto Note 1.
	8¾"-16½"), 22cm to 45cm (about8¾"-17¾") or 40cm to 52cm (about15¾"-20½").It is intended for adult indoor useonly.	8¾"-12½"), 22cm to 42cm (about8¾"-16½") or 22cm to 45cm (about8¾"-17¾").The cuff with arm circumferencerange of 16~~36cm is intended forchildren older than 6 years old oradults.The cuffs with arm circumferencerange of 22~~32cm or 22~~42cm or22~~45cm, which are intended foradult population.It is intended indoor use only.
PatientPopulation	Adult	Population at or over 3 years old	Similar, referto Note 2.
Principle	Oscillometric method	Oscillometric method	Same
AnatomicalSite	Upper Arm	Upper Arm	Same
Where used(hospital,home,ambulance,etc.)	Home	Home	Same
Power Supply	4*1.5V AAA batteries;Or by DC 5V adapter	4*1.5V AAA batteries;Or by DC 5V adapter	Same
Human Factors	Blood pressure	Blood pressure	Same
MeasurementItems	Measuring systolic and diastolicblood pressure and pulse rate ofintended population, includingirregular pulse rhythm detection.	Measuring systolic and diastolicblood pressure and pulse rate ofintended population, includingirregular pulse rhythm detection.	Same
Cuff Deflation	Automatic deflation	Automatic deflation	Same
Blood PressureMeasurement	0mmHg ~ 299mmHg,5°C - 40°C within ±3mmHg (0.4kPa)	0mmHg ~ 299mmHg,5°C - 40°C within ±3mmHg (0.4kPa)	Same
Pulse RateMeasurement	40-199 beat/minute, ±5%	40-199 beat/minute, ±5%	Same
Display	LCD	LCD	Same
Memory	2×199	2×199	Same
OperationEnvironment	Temperature: 5°C~40°C;Relative Humidity: 15%~90% RH;	Temperature: 5°C~40°C;Relative Humidity: 15%~90% RH;	Same
	Atmospheric: 700hPa~1060hPa	Atmospheric: 700hPa~1060hPa
	Temperature: -20°C~60°C;	Temperature: -20°C~60°C;
Storage and	Relative humidity≤93%RH,	Relative humidity≤93%RH,
transportation	non-condensing;	non-condensing;	Same
Environment	Atmospheric: 500hPa~1060hPa	Atmospheric: 500hPa~1060hPa
Performance	Compliance with IEC 80601-2-30	Compliance with IEC 80601-2-30	Same
Clinical	Compliance with ISO 81060-2	Compliance with ISO 81060-2	Same
Biocompatibilit	All patient contact parts meet the	All patient contact parts meet the
y	requirements of ISO 10993-1/5/10/23	requirements of ISO 10993-1/5/10/23	Same
Electrical	Compliance with IEC 60601-1 and	Compliance with IEC 60601-1 and
Safety	IEC 60601-1-11	IEC 60601-1-11	Same
EMC	Compliance with IEC 60601-1-2	Compliance with IEC 60601-1-2	Same
Wireless	Bluetooth	Bluetooth	Same

Comparison to Predicate Device 6.

{6}------------------------------------------------

{7}------------------------------------------------

Note 1:

The subject device shares a similar intended use with the predicate device, and the substantial difference between the subject device and the predicate device regarding the intended use lies in the arm circumference range and patient population. However, the range of the intented patient population of the subject device is within that of the predicate device, and used on its intended patient population with the intended arm circumference, the subject device with matched cuffs has also been validated according to IEC 80601-2-30 and ISO 81060-2. As demonstrated in relevant test reports, the difference here does not raise any issues concerning safety and effectiveness.

Note 2:

Although there are some differences between the intended patient population of the subject device and the predicate device, the range of the intended patient population of the subject device is within that of the predicate device, and used on its intended patient population with the intended arm circumference, the subject device with matched cuffs has also been validated according to IEC 80601-2-30 and ISO 81060-2. As demonstrated in relevant test reports, the difference here does not raise any issues concerning safety and effectiveness.

Conclusion: _

Based on the comparison and analysis in this submission, it can be concluded that: the subject device is substantially equivalent to the predicate device and reference device regarding safety and effectiveness.

7. Performance Data

The following performance data were provided in support of the substantial equivalence determination:

{8}------------------------------------------------

Biocompatibility testing:

The biocompatibility evaluation for the device was conducted in accordance with the FDA Guidance for Industry and Food and Drug Administration Staff: Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process". The biocompatibility testing includes the following tests:

Cytotoxicity
Sensitization
Irritation

The subject device is considered as surface contacting for a duration of exceed 24 hours but not exceed 30 days.

Non-clinical data

The device has been tested according to following standards:

IEC 60601-1: Medical electrical equipment - Part 1: General requirements for basic safety and essential performance
IEC 60601-1-2: Medical electrical equipment - Part 1-2: General requirement for basic safety and essential performance - Collateral standard: Electromagnetic compatibility -Requirements and tests
IEC 80601-2-30: Medical electrical equipment -- Particular requirements for basic safety and essential performance of automated non-invasive sphygmomanometers.
IEC 60601-1-11: Medical electrical equipment - Part 1-11: General requirements for basic safety and essential performance – Collateral standard: Requirements for medical electrical equipment and medical electrical systems used in the home healthcare environment
FDA Guidance for Non-Automated Sphygmomanometer

Wireless testing

47 CFR Part 15, Subpart C
Radio Frequency Wireless Technology in Medical Devices: Guidance for Industry and Food ● and Drug Administration Staff (August 14, 2013)

Clinical data

The device was tested according to ISO 81060-2:2018/Amd.1:2020. Non-invasive sphygmomanometers - Part 2: Clinical validation of intermittent automated measurement type. Two clinical studies were performed on the device matching with different models of cuff. The study population consisted of 87 and 91 qualified subjects respectively. 258 datasets were collected from 87 subjects with aged 58.8+8.4. The mean differences between reference BPs and device readings were -0.77±2.09/-0.08±1.69mmHg for systolic BP (SBP)/diastolic BP (DBP) of criterion 1, and -0.77± 1.58/-0.08±1.17mmHg for SBP/DBP of criterion 2. 272 datasets were collected from 91 subjects with aged 50.6±12.04. The mean differences between reference BPs and device readings were 0.2+2.96/0.76±3.42mmHg for systolic BP (SBP)/diastolic BP (DBP) of criterion 1, and 0.2± 2.46/0.76±2.83mHg for SBP/DBP of criterion 2. TMB-2287-B fulfilled both validation criteria 1 and 2 of the ISO 81060-2:2018/Amd.1:2020.

{9}------------------------------------------------

8. Conclusion

Based on the information presented in this 510(k) premarket notification submission, a conclusion can be drawn that the proposed subject device is considered substantially equivalent to the predicate device. The differences between the subject device and the predicate devices were successfully tested with relevant standards and FDA guidance, and do not affect equivalent safety and effectiveness or raise new issues concerning safety and effectiveness.

Regulation Number and Section

§ 870.1130 Noninvasive blood pressure measurement system.

(a)
Identification. A noninvasive blood pressure measurement system is a device that provides a signal from which systolic, diastolic, mean, or any combination of the three pressures can be derived through the use of tranducers placed on the surface of the body.(b)
Classification. Class II (performance standards).